Table 3.

Heartburn symptom severity according to twice-daily diary entries at baseline and during treatment

	NERD						EO
	Dexlansoprazole MR 30 mg			Placebo			Dexlansoprazole MR 60 mg			Lansoprazole 30 mg
	BMI, kg/m2						BMI, kg/m2
Variable (median)	<25	25 to <30	≥30	<25	25 to <30	≥30	<25	25 to <30	≥30	<25	25 to <30	≥30
Baseline 24-h symptom severity	n = 89	n = 107	n = 115	n = 100	n = 86	n = 123	n = 273	n = 481	n = 553*	n = 252	n = 501	n = 549*
	1.14	1.21	1.36	1.32	1.42	1.50	1.07	1.17	1.43	1.00	1.25	1.43
Mean symptom severity during treatment	n = 89	n = 107	n = 115	n = 101	n = 86	n = 123	n = 282	n = 480	n = 556†	n = 252	n = 517	n = 551
	0.50	0.33	0.38	0.80	0.99	0.97	0.19	0.13	0.12	0.20	0.15	0.14

BMI, body mass index; EO, erosive oesophagitis; NERD, non-erosive oesophageal reflux disease.

Severity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe.

Statistically significant differences among BMI categories within treatment group using Kruskal–Wallis test at *P < 0.001; †P = 0.013.